GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » Cash Flow from Investing

Lifecore Biomedical (Lifecore Biomedical) Cash Flow from Investing : $-4.8 Mil (TTM As of May. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Lifecore Biomedical Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in May. 2023, Lifecore Biomedical spent $9.2 Mil on purchasing property, plant, equipment. It gained $0.0 Mil from selling property, plant, and equipment. It spent $0.0 Mil on purchasing business. It gained $1.0 Mil from selling business. It spent $0.0 Mil on purchasing investments. It gained $0.0 Mil from selling investments. It paid $0.0Mil for net Intangibles purchase and sale. And it received $0.0 Mil from other investing activities. In all, Lifecore Biomedical spent $8.2 Mil on investment activities in financial market and operating subsidiaries for the three months ended in May. 2023.


Lifecore Biomedical Cash Flow from Investing Historical Data

The historical data trend for Lifecore Biomedical's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifecore Biomedical Cash Flow from Investing Chart

Lifecore Biomedical Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -96.80 -23.89 -12.31 79.96 -4.81

Lifecore Biomedical Quarterly Data
Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.81 0.21 -3.25 6.39 -8.16

Lifecore Biomedical Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Lifecore Biomedical's Cash Flow from Investing for the fiscal year that ended in May. 2023 is calculated as:

Lifecore Biomedical's Cash Flow from Investing for the quarter that ended in May. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in May. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lifecore Biomedical  (NAS:LFCR) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Lifecore Biomedical's purchase of property, plant, equipment for the three months ended in May. 2023 was $-9.2 Mil. It means Lifecore Biomedical spent $9.2 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Lifecore Biomedical's sale of property, plant, equipment for the three months ended in May. 2023 was $0.0 Mil. It means Lifecore Biomedical gained $0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Lifecore Biomedical's purchase of business for the three months ended in May. 2023 was $0.0 Mil. It means Lifecore Biomedical spent $0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Lifecore Biomedical's sale of business for the three months ended in May. 2023 was $1.0 Mil. It means Lifecore Biomedical gained $1.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Lifecore Biomedical's purchase of investment for the three months ended in May. 2023 was $0.0 Mil. It means Lifecore Biomedical spent {stock_data.stock.currency_symbol}}0.0 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Lifecore Biomedical's sale of investment for the three months ended in May. 2023 was $0.0 Mil. It means Lifecore Biomedical gained $0.0 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Lifecore Biomedical's net Intangibles purchase and sale for the three months ended in May. 2023 was $0.0 Mil. It means Lifecore Biomedical paid $0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Lifecore Biomedical's cash from discontinued investing activities for the three months ended in May. 2023 was 0.0 Mil. It means Lifecore Biomedical paid $0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Lifecore Biomedical's cash from other investing activities for the three months ended in May. 2023 was $0.0 Mil. It means Lifecore Biomedical received $0.0 Mil from other investing activities.


Lifecore Biomedical Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Lifecore Biomedical (Lifecore Biomedical) Business Description

Traded in Other Exchanges
N/A
Address
3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid.
Executives
Raymond T. White director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. Ii director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Christopher S Kiper director 12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Wynnefield Partners Small Cap Value Lp I 10 percent owner 450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Raymond H Diradoorian director C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Joshua Schechter director C/O THE PANTRY, INC., 305 GREGSON DRIVE, CARY NC 27511
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780
John D Morberg officer: Chief Financial Officer C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Albert D. Bolles director CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
James G Hall officer: Executive Vice President 3515 LYMAN BLVD., CHASKA MN 55318

Lifecore Biomedical (Lifecore Biomedical) Headlines